U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07906041) titled 'Tirzepatide and Organ-specific Biological Aging' on Oct. 26.
Brief Summary: The purpose of this study is to evaluate blood-based measures of organ-specific biological age, with a particular focus on the brain, and to investigate their relationship with established clinical indicators of health and their response to treatment with tirzepatide.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Longevity
Preventive Medicine
Biological Ageing
Intervention:
DRUG: Tirzepatide
Tirzepatide, a dual GLP-1/GIP receptor agonist, is administered by subcutaneous injection once weekly for 6 months. The starting dose is 2.5 ...